H. pylori and oesophageal disease: what patients should know

The link between Helicobacter pylori and oesophageal disease is clinically important, but often misunderstood. This bacterium mainly colonises the stomach, where chronic infection can cause gastritis, peptic ulcers, gastric adenocarcinoma and MALT lymphoma. It does not directly infect the oesophagus.

Because the stomach and oesophagus function as one digestive unit, H. pylori can influence symptoms, ulcer risk and treatment. It can also complicate the use of acid-suppressing medicines. Eradication, however, is not a cure for reflux or oesophagitis, and assuming otherwise may delay the correct diagnosis.

How infection changes gastric and oesophageal risk

After entering the stomach’s protective mucus layer, H. pylori produces urease and triggers chronic inflammation. Many infections cause no symptoms, while others produce upper abdominal burning, meal-related pain, nausea or early fullness. Atrophic gastritis and intestinal metaplasia can develop over time in some people.

Medication interactions are particularly important. H. pylori increases the risk of ulcers, especially when combined with non-steroidal anti-inflammatory drugs such as ibuprofen. Eradication is therefore important in peptic ulcer disease, but it does not remove every cause of oesophageal inflammation.

Why the reflux relationship is not straightforward

Some studies report an inverse association between H. pylori and oesophageal adenocarcinoma: populations with more gastric infection frequently have more gastric cancer but less reflux-related oesophageal cancer. This pattern does not prove that the bacterium prevents oesophageal disease, since diet, obesity, smoking and medication use also differ between populations.

Possible biological effects include changes in gastric acidity, inflammation and the intestinal microbiome. Meanwhile, proton pump inhibitors alter acid production and the microbiome in different ways. Coexisting reflux may continue after eradication, so an improvement in symptoms cannot establish that H. pylori caused the original problem.

Symptoms that overlap and symptoms that demand attention

Reflux, gastritis, peptic ulcer disease and functional dyspepsia can all cause burning, bloating, nausea or discomfort after eating. Upper abdominal pain that improves or worsens with food may originate in the stomach rather than the oesophagus. No combination of routine symptoms reliably identifies H. pylori infection.

Difficulty swallowing, food sticking, vomiting blood, black tarry stools, persistent vomiting, unexplained weight loss or iron-deficiency anaemia require prompt medical assessment. These features may indicate ulcers, bleeding, narrowing, inflammation or malignancy and should not be attributed to H. pylori without investigation.

Diagnosing infection and other oesophageal disease

Urea breath testing and stool antigen testing are commonly used to detect active infection. Blood antibody tests are less useful because they may remain positive after an old infection has been cleared. Proton pump inhibitors, antibiotics and bismuth can suppress test results, so medication washout periods should be arranged when it is clinically safe.

Endoscopy with biopsy may be needed for people with alarm symptoms, selected patients over 50 with new dyspepsia, or those requiring specialist assessment. Biopsies can identify H. pylori, assess gastritis and detect Barrett’s oesophagus or other pathology. Eradication should be confirmed with a breath or stool test at least four weeks after antibiotics, usually after withholding acid suppression for two weeks if safe.

Choosing eradication treatment in Australia

Current Australian guidance often favours a seven-day bismuth quadruple regimen when clarithromycin resistance is unknown or likely. This combines a proton pump inhibitor with bismuth, tetracycline and metronidazole. A clarithromycin triple regimen may be suitable when susceptibility supports its use, while penicillin allergy can influence the choice. Previous antibiotic exposure, drug interactions and local resistance patterns also matter.

Australian pharmacies can supply proton pump inhibitors and the bismuth preparations used in eradication regimens, while antibiotics require prescription. The Pharmaceutical Benefits Scheme subsidises many proton pump inhibitors, although a complete eradication combination may involve additional costs. The Therapeutic Goods Administration regulates the safety, quality and advertising of medicines, while state and territory poisons laws govern antibiotic supply and prescribing.

Daily habits, medicines and transmission

The exact route of H. pylori transmission remains uncertain, although oral-to-oral and faecal-to-oral spread are considered plausible. Australia’s generally reliable drinking-water and food-safety systems reduce environmental exposure. Ordinary handwashing and safe food preparation are sensible, but routine household disinfection or special cleaning of utensils is not routinely recommended.

Smoking and NSAID use increase ulcer risk, particularly when H. pylori is present. Alcohol, large meals and eating close to bedtime can aggravate reflux in susceptible people. Long-term pain medicines and anticoagulants deserve medical review. Probiotics may reduce some antibiotic-associated digestive symptoms, but they do not replace eradication therapy or prescribed oesophageal treatment.

A practical plan for Australians

A general practitioner can assess persistent reflux or dyspepsia and arrange breath testing, stool testing or specialist review. Major cities such as Melbourne, Sydney, Brisbane, Perth and Adelaide offer public and private diagnostic pathways, while regional and remote patients may face longer waits for endoscopy or need to travel. Telehealth can help with initial assessment and treatment planning where local testing is unavailable.

Persistent symptoms should be distinguished from an infection, and confirmed infection should receive an appropriate eradication regimen followed by testing for cure. Anyone with alarm features should seek urgent assessment rather than relying on self-treatment. The practical takeaway is to investigate the cause of symptoms, eradicate H. pylori when indicated, confirm clearance, and avoid assuming that the bacterium explains every oesophageal problem.